News and Events Recent News Apr 16, 2021 Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results Apr 15, 2021 Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform Mar 1, 2021 Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia View More » Recent Events May 4, 2021 Arrowhead Pharmaceuticals 2021 Second Quarter Results Feb 4, 2021 Arrowhead Pharmaceuticals 2021 First Quarter Results Dec 12, 2020 20th Gordon L. Snider Critical Issues Workshop – The Promise of Gene-based Interventions in Alpha-1 Antitrypsin Deficiency View More »
Apr 15, 2021 Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
Mar 1, 2021 Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Dec 12, 2020 20th Gordon L. Snider Critical Issues Workshop – The Promise of Gene-based Interventions in Alpha-1 Antitrypsin Deficiency